東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Targeting EGFR and ErbB2 by small mo...

Zhou, Yunfei.

FindBook

Google Book

Amazon

博客來

Targeting EGFR and ErbB2 by small molecule tyrosine kinase inhibitors in human colon cancer.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Targeting EGFR and ErbB2 by small molecule tyrosine kinase inhibitors in human colon cancer./
作者:	Zhou, Yunfei.
面頁冊數:	157 p.
附註:	Adviser: Michael G. Brattain.
Contained By:	Dissertation Abstracts International66-08B.
標題:	Biology, Cell. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3184674
ISBN:	9780542257858

Targeting EGFR and ErbB2 by small molecule tyrosine kinase inhibitors in human colon cancer.
Zhou, Yunfei.

Targeting EGFR and ErbB2 by small molecule tyrosine kinase inhibitors in human colon cancer. - 157 p.

Adviser: Michael G. Brattain.

Thesis (Ph.D.)--State University of New York at Buffalo, 2005.

With the understanding of the molecular pathogenesis of colorectal cancer, novel molecular targeted therapies are being developed that may improve treatment of colorectal cancer. The identification of a causal role of deregulated EGFR signaling in tumorigenesis and progression of colorectal cancer provides the rationale to target this proto-oncogene as a potential treatment. However, despite the fact that up to 80% colorectal cancers appear to utilize EGFR for tumor growth, single agent anti-EGFR monoclonal antibodies achieved at best a 10% response rate and no EGFR tyrosine kinase inhibitors (TKIs) have shown activity in this disease so far. The hypothesis of this study is that aberrant ErbB2 signaling may provide for a potential drug resistance mechanism to EGFR single TKIs. Therefore, targeting both EGFR and ErbB2 kinase simultaneously by small molecule TKIs could achieve superior efficacy than single EGFR TKIs in colorectal cancer. This study examined this hypothesis using a combinational approach for EGFR and ErbB2 TKIs in two human colorectal carcinoma cell models, FET6alphaS26X and GEO. Both cell lines express multiple ErbB receptors, but not ErbB4, and harbor a deregulation of ErbB autocrine loop of TGFalpha/EGFR and/or heregulin/ErbB3. A synergistic effect of inhibition on tumor cell proliferation was achieved by a combination of EGFR and ErbB2 TKIs, AG1478 and AG879, in both cell models. Furthermore, the synergy of inhibition on cell proliferation was associated with apoptosis induction in both cell models, arguing for a general benefit of combination in colorectal cancer cells expressing multiple ErbB receptors. Exploration of the mechanisms of synergy revealed that combination treatment sufficiently blocked both EGFR and ErbB2 activation arising from heterodimerization. Downstream signaling mediated through ErbB receptors, including MAPK, AKT and PLC-gamma pathways, are suppressed by the combination treatment as well. The novel dual EGFR and ErbB2 TKI, GW572016 was shown to have a superior efficacy to single ErbB TKIs and an equivalent efficacy as the combination approach in both cell models. The in vitro efficacy of GW572016 was translated into tumor xenograft studies demonstrating the anti-tumor effect of this compound. In summary, our data support the investigation of the dual EGFR and ErbB2 TKI GW572016 for colorectal cancer treatment.

ISBN: 9780542257858Subjects--Topical Terms:

1017686
Biology, Cell.

Targeting EGFR and ErbB2 by small molecule tyrosine kinase inhibitors in human colon cancer.
LDR:03315nam 2200277 a 45 001 943636
005 20110520
008 110520s2005 ||||||||||||||||| ||eng d
020 $a 9780542257858
035 $a (UMI)AAI3184674
035 $a AAI3184674
040 $a UMI $c UMI
100 1 $a Zhou, Yunfei. $3 1267669
245 1 0 $a Targeting EGFR and ErbB2 by small molecule tyrosine kinase inhibitors in human colon cancer.
300 $a 157 p.
500 $a Adviser: Michael G. Brattain.
500 $a Source: Dissertation Abstracts International, Volume: 66-08, Section: B, page: 4045.
502 $a Thesis (Ph.D.)--State University of New York at Buffalo, 2005.
520 $a With the understanding of the molecular pathogenesis of colorectal cancer, novel molecular targeted therapies are being developed that may improve treatment of colorectal cancer. The identification of a causal role of deregulated EGFR signaling in tumorigenesis and progression of colorectal cancer provides the rationale to target this proto-oncogene as a potential treatment. However, despite the fact that up to 80% colorectal cancers appear to utilize EGFR for tumor growth, single agent anti-EGFR monoclonal antibodies achieved at best a 10% response rate and no EGFR tyrosine kinase inhibitors (TKIs) have shown activity in this disease so far. The hypothesis of this study is that aberrant ErbB2 signaling may provide for a potential drug resistance mechanism to EGFR single TKIs. Therefore, targeting both EGFR and ErbB2 kinase simultaneously by small molecule TKIs could achieve superior efficacy than single EGFR TKIs in colorectal cancer. This study examined this hypothesis using a combinational approach for EGFR and ErbB2 TKIs in two human colorectal carcinoma cell models, FET6alphaS26X and GEO. Both cell lines express multiple ErbB receptors, but not ErbB4, and harbor a deregulation of ErbB autocrine loop of TGFalpha/EGFR and/or heregulin/ErbB3. A synergistic effect of inhibition on tumor cell proliferation was achieved by a combination of EGFR and ErbB2 TKIs, AG1478 and AG879, in both cell models. Furthermore, the synergy of inhibition on cell proliferation was associated with apoptosis induction in both cell models, arguing for a general benefit of combination in colorectal cancer cells expressing multiple ErbB receptors. Exploration of the mechanisms of synergy revealed that combination treatment sufficiently blocked both EGFR and ErbB2 activation arising from heterodimerization. Downstream signaling mediated through ErbB receptors, including MAPK, AKT and PLC-gamma pathways, are suppressed by the combination treatment as well. The novel dual EGFR and ErbB2 TKI, GW572016 was shown to have a superior efficacy to single ErbB TKIs and an equivalent efficacy as the combination approach in both cell models. The in vitro efficacy of GW572016 was translated into tumor xenograft studies demonstrating the anti-tumor effect of this compound. In summary, our data support the investigation of the dual EGFR and ErbB2 TKI GW572016 for colorectal cancer treatment.
590 $a School code: 0656.
650 4 $a Biology, Cell. $3 1017686
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0379
690 $a 0992
710 2 $a State University of New York at Buffalo. $3 1017814
773 0 $t Dissertation Abstracts International $g 66-08B.
790 $a 0656
790 1 0 $a Brattain, Michael G., $e advisor
791 $a Ph.D.
792 $a 2005
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3184674